RA CAPITAL MANAGEMENT, L.P. - 06 Feb 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
TYRA
Transactions as of
06 Feb 2024
Net transactions value
+$61,387,604
Form type
4
Filing time
08 Feb 2024, 17:16:02 UTC
Previous filing
12 Jan 2024
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Award $41,373,817 +3,180,155 +60% $13.01 8,477,275 06 Feb 2024 See footnotes F1, F2
holding TYRA Common Stock 1,496,613 06 Feb 2024 See footnotes F2, F3
holding TYRA Common Stock 442,721 06 Feb 2024 See footnotes F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Pre-Funded Warrants (Right to Buy) Award $20,013,787 +1,538,457 $13.01 1,538,457 06 Feb 2024 Common Stock 1,538,457 $0.001000 See footnotes F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F2 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3 These securities are held directly by the Nexus Fund.
F4 These securities are held directly by the Account.
F5 The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Remarks:

Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.